Ramucirumab with eribulin versus eribulin in locally recurrent or metastatic breast cancer previously treated with anthracycline and taxane therapy: A multicenter, randomized, phase II study

Authors

Foluso Ademuyiwa, Washington University School of Medicine in St. Louis
et al

Journal

Clinical Breast Cancer

Publication Date

2016

Volume

16

Issue

6

Inclusive Pages

471-479.e1

Document Type

Open Access Publication

DOI

10.1016/j.clbc.2016.07.005

Rights and Permissions

Yardley, D.A., et al (2016) Ramucirumab With Eribulin Versus Eribulin in Locally Recurrent or Metastatic Breast Cancer Previously Treated With Anthracycline and Taxane Therapy: A Multicenter, Randomized, Phase II Study. Clinical Breast Cancer, 16(6): 471-479.e1 http://dx.doi.org/10.1016/j.clbc.2016.07.005 Copyright 2016 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). http://dx.doi.org/10.1016/j.clbc.2016.07.005

Recommended Citation

Ademuyiwa, Foluso and et al, "Ramucirumab with eribulin versus eribulin in locally recurrent or metastatic breast cancer previously treated with anthracycline and taxane therapy: A multicenter, randomized, phase II study." Clinical Breast Cancer. 16, 6. 471-479.e1. (2016).
https://digitalcommons.wustl.edu/open_access_pubs/5406